Programmed cell death-1 inhibitor combination treatment for recurrent proficient mismatch repair/ miscrosatellite-stable type endometrial cancer: A case report

doi:10.12998/wjcc.v10.i21.7474

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 21

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7165)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-1) series.

Item

Count

PDF

333

WORD

HTML

2649

Figures (1-4)

592

Tables (1-1)

593

Sum=4228

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

281

Download

777

Sum=1058

Publishing Process of This Article

Item

Count

Browse

451

Download

1428

Sum=1879

Jul 26, 2022 (publication date) through Oct 25, 2025

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Case Report

World J Clin Cases. Jul 26, 2022; 10(21): 7474-7482
Published online Jul 26, 2022. doi: 10.12998/wjcc.v10.i21.7474

Table 1 Genetic testing of blood and tissue samples

Tests	Results
Next generation sequencing
PD-L1 expression	Negative
Mismatch repair	pMMR
Tumor mutation burden	2.09 Muts/Mb
MicroSatelite Instability	MSS
Human leukocyte antigen typing	Heterogeneous
Tumor neoantigens	6
POLE	Negative
TP53	Negative
Predictive/prognostic biomarkers
MDM4	4 amplifications
AKT1	83.05% p. Glu17 Lys mutation
CTNNB1	37.06% p. Ser37Ala mutation

PD-L1: Programmed cell death-Ligand 1; POLE: Polymerase epsilon; TP: Tumor protein; MDM: Murine double minute; AKT: V-Akt murine thymoma viral oncogene homolog; CTNNB: Catenin beta; pMMR: Proficient mismatch repair; Mb: Mega byte; MSS: Miscrosatellite-stable.

Full Size Table

Citation: Zhai CY, Yin LX, Han WD. Programmed cell death-1 inhibitor combination treatment for recurrent proficient mismatch repair/ miscrosatellite-stable type endometrial cancer: A case report. World J Clin Cases 2022; 10(21): 7474-7482
URL: https://www.wjgnet.com/2307-8960/full/v10/i21/7474.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i21.7474